Related Experiment Video
Updated: May 12, 2026
07:59
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
Autologous CD133+ cells augment the effect of portal embolization
M C Canepa1, P Quaretti, C Perotti
1Department of General Surgery I, University of Pavia, Pavia, Italy. canepamaria@libero.it
Minerva Chirurgica
|April 25, 2013
Summary
Combining portal vein embolization (PVE) with autologous stem cells significantly enhances liver regeneration. This approach may improve surgical outcomes for patients with liver tumors and limited future liver remnant (FLRV).
Area of Science:
- Hepatology
- Regenerative Medicine
- Surgical Oncology
Background:
- Liver tumor resection is standard treatment, but limited future liver remnant (FLRV) increases complication risk.
- Portal vein embolization (PVE) is used to increase FLRV, but its efficacy can be limited.
- Cell therapies offer novel approaches to enhance tissue regeneration.
Purpose of the Study:
- To evaluate the synergistic effect of combining PVE with autologous CD133+ cell coadministration.
- To assess the impact of this combined therapy on liver regeneration and tumor resectability.
Main Methods:
- Sixteen patients with liver malignancy and insufficient FLRV (<30% or 40%) were enrolled.
- Autologous CD133+ cells were mobilized and collected following G-CSF administration.
- Cells were coadministered with PVE to non-occluded liver segments; volumetric CT scans monitored FLRV changes.
Main Results:
- Patients receiving combined PVE and cell therapy (N.=6) demonstrated significantly increased liver volume gain compared to PVE alone (N.=10) (P<0.001).
- This indicates enhanced liver regeneration in the combined treatment group.
Conclusions:
- Autologous stem cell administration can augment liver regeneration.
- Combined PVE and autologous stem cell therapy holds clinical potential for improving liver tumor resectability.
- Further research is warranted to optimize this regenerative approach.
